Skip to main content
SpringerLink
Log in

Ion Mobility Lipoprotein Analysis

  • Chapter
  • First Online:
Therapeutic Lipidology

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

Measurement of plasma levels of lipoprotein particles, particularly low-density lipoproteins (LDL) and their particle size subfractions, can provide assessment of cardiovascular disease (CVD) risk beyond that provided by standard lipid profiles. Ion mobility is a novel technology that directly measures concentration of lipoprotein particles as a function of particle diameter across the entire spectrum of plasma lipoproteins, from small high-density lipoproteins to larger very-low-density lipoproteins. This technique is based on counting individual lipoprotein particles generated by electrospray and separated by size across a differential voltage gradient. In several clinical studies, lipoprotein particle subfraction levels determined by ion mobility have been associated with CVD events as well as measures of atherosclerotic burden. The findings have corroborated studies using other methods that point to the CVD risk associated with increased levels of small LDL particles and other features of the atherogenic dyslipidemia that is characteristic of individuals with abdominal adiposity, insulin resistance, and type 2 diabetes mellitus. Hence, ion mobility has the potential to enhance CVD risk assessment, to detect residual risk for patients who are being treated with lipid-lowering therapies, and to further dissect the complex role of lipoproteins in the pathogenesis of CVD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gofman JW, Lindgren F. The role of lipids and lipoproteins in atherosclerosis. Science. 1950;111(2877):166–71.

    Article  CAS  Google Scholar 

  2. Musliner TA, Krauss RM. Lipoprotein subspecies and risk of coronary disease. Clin Chem. 1988;34(8B):B78–83.

    CAS  PubMed  Google Scholar 

  3. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 2004;109(23 Suppl 1):III2–7.

    PubMed  Google Scholar 

  4. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 1982;23(1):97–104.

    CAS  PubMed  Google Scholar 

  5. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43(9):1363–79.

    Article  CAS  Google Scholar 

  6. McNamara JR, Small DM, Li Z, Schaefer EJ. Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B. J Lipid Res. 1996;37(9):1924–35.

    CAS  PubMed  Google Scholar 

  7. Krauss RM. Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. Am Heart J. 1987;113(2 Pt 2):578–82.

    Article  CAS  Google Scholar 

  8. Shen MM, Krauss RM, Lindgren FT, Forte TM. Heterogeneity of serum low density lipoproteins in normal human subjects. J Lipid Res. 1981;22(2):236–44.

    CAS  PubMed  Google Scholar 

  9. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82(2):495–506.

    Article  CAS  Google Scholar 

  10. Lamarche B, St-Pierre AC, Ruel IL, Cantin B, Dagenais GR, Despres JP. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol. 2001;17(8):859–65.

    CAS  PubMed  Google Scholar 

  11. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276(11):882–8.

    Article  CAS  Google Scholar 

  12. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002;106(15):1930–7.

    Article  CAS  Google Scholar 

  13. Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol. 2002;22(7):1175–80.

    Article  CAS  Google Scholar 

  14. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC Jr, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis. 2007;192(1):211–7.

    Article  CAS  Google Scholar 

  15. Hirayama S, Miida T. Small dense LDL: an emerging risk factor for cardiovascular disease. Clin Chim Acta. 2012;414:215–24.

    Article  CAS  Google Scholar 

  16. Hoogeveen RC, Gaubatz JW, Sun W, Dodge RC, Crosby JR, Jiang J, et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014;34(5):1069–77.

    Article  CAS  Google Scholar 

  17. Tsai MY, Steffen BT, Guan W, McClelland RL, Warnick R, McConnell J, et al. New automated assay of small dense low-density lipoprotein cholesterol identifies risk of coronary heart disease: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2014;34(1):196–201.

    Article  CAS  Google Scholar 

  18. Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, et al., Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.Eur Heart J. 2020;41(24):2313–30.

    Google Scholar 

  19. Parish S, Offer A, Clarke R, Hopewell JC, Hill MR, Otvos JD, et al., Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation. 2012;125(20):2469–78.

    Google Scholar 

  20. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337–45.

    Article  Google Scholar 

  21. Master SR, Rader DJ. Beyond LDL cholesterol in assessing cardiovascular risk: apo B or LDL-P? Clin Chem. 2013;59(5):723–5.

    Article  CAS  Google Scholar 

  22. Clouet-Foraison N, Gaie-Levrel F, Gillery P, Delatour V. Advanced lipoprotein testing for cardiovascular diseases risk assessment: a review of the novel approaches in lipoprotein profiling. Clin Chem Lab Med. 2017;55(10):1453–64.

    Article  CAS  Google Scholar 

  23. Caulfield MP, Li S, Lee G, Blanche PJ, Salameh WA, Benner WH, et al. Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. Clin Chem. 2008;54(8):1307–16.

    Article  CAS  Google Scholar 

  24. Caulfield MP, Li S, Lee G, Blanche PA, Salameh WA, Benner WH, et al. In reply. Clin Chem. 2008;54(12):2088–9.

    Article  CAS  Google Scholar 

  25. Mora S, Caulfield MP, Wohlgemuth J, Chen Z, Superko HR, Rowland CM, et al. Atherogenic lipoprotein subfractions determined by ion mobility and first cardiovascular events after random allocation to high-intensity statin or placebo: the justification for the use of statins in prevention: an intervention trial evaluating Rosuvastatin (JUPITER) trial. Circulation. 2015;132(23):2220–9.

    Article  CAS  Google Scholar 

  26. Musunuru K, Orho-Melander M, Caulfield MP, Li S, Salameh WA, Reitz RE, et al. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol. 2009;29(11):1975–80.

    Article  CAS  Google Scholar 

  27. Williams PT, Zhao XQ, Marcovina SM, Otvos JD, Brown BG, Krauss RM. Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease. Atherosclerosis. 2014;233(2):713–20.

    Article  CAS  Google Scholar 

  28. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992;326(4):242–50.

    Article  CAS  Google Scholar 

  29. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.

    Article  Google Scholar 

  30. Melander O, Shiffman D, Caulfield MP, Louie JZ, Rowland CM, Devlin JJ, et al. Low-density lipoprotein particle number is associated with cardiovascular events among those not classified into statin benefit groups. J Am Coll Cardiol. 2015;65(23):2571–3.

    Article  CAS  Google Scholar 

  31. Shiffman D, Louie JZ, Caulfield MP, Nilsson PM, Devlin JJ, Melander O. LDL subfractions are associated with incident cardiovascular disease in the Malmo prevention project study. Atherosclerosis. 2017;263:287–92.

    Article  CAS  Google Scholar 

  32. Saran R, Robinson B, Abbott KC, Agodoa LY, Albertus P, Ayanian J, et al. US renal data system 2016 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2017;69(3 Suppl 1):A7–8.

    Article  Google Scholar 

  33. Noori N, Caulfield MP, Salameh WA, Reitz RE, Nicholas SB, Molnar MZ, et al. Novel lipoprotein subfraction and size measurements in prediction of mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2011;6(12):2861–70.

    Article  CAS  Google Scholar 

  34. Benson M, Hossain J, Caulfield MP, Damaso L, Gidding S, Mauras N. Lipoprotein subfractions by ion mobility in lean and obese children. J Pediatr. 2012;161(6):997–1003.

    Article  CAS  Google Scholar 

  35. Canas, JA, Ross, JL, Taboada, MV, Sikes, KM, Damaso, LC, Hossain, J, et al., A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes. Pediatr Diabetes, 2015;16(2):79–89.

    Google Scholar 

  36. El Khoudary SR, Ceponiene I, Samargandy S, Stein JH, Li D, Tattersall MC, et al. HDL (high-density lipoprotein) metrics and atherosclerotic risk in women. Arterioscler Thromb Vasc Biol. 2018;38(9):2236–44.

    Article  Google Scholar 

  37. Rowland CM, Shiffman D, Caulfield M, Garcia V, Melander O, Hastie T. Association of cardiovascular events and lipoprotein particle size: development of a risk score based on functional data analysis. PLoS ONE. 2019;14(3):e0213172.

    Article  CAS  Google Scholar 

  38. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–53.

    Article  CAS  Google Scholar 

  39. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331–9.

    Article  CAS  Google Scholar 

  40. Pati U, Pati N. Lipoprotein(a), atherosclerosis, and apolipoprotein(a) gene polymorphism. Mol Genet Metab. 2000;71(1–2):87–92.

    Article  CAS  Google Scholar 

  41. Guadagno PA, Summers Bellin EG, Harris WS, Dayspring TD, Hoefner DM, Thiselton DL, et al. Validation of a lipoprotein(a) particle concentration assay by quantitative lipoprotein immunofixation electrophoresis. Clin Chim Acta. 2015;439:219–24.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA

    Sarah M. King

  2. Departments of Pediatrics and Medicine, University of California, San Francisco, San Francisco, CA, USA

    Ronald M. Krauss

Authors
  1. Sarah M. King
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronald M. Krauss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ronald M. Krauss .

Editor information

Editors and Affiliations

  1. The University of Chicago Pritzker School of Medicine, Chicago, IL, USA

    Michael H. Davidson

  2. Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins Univerity School of Medicine, Baltimore, MD, USA

    Peter P. Toth

  3. Department of Applied Health Science, Indiana University School of Public Health, Bloomington, IN, USA

    Kevin C. Maki

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

King, S.M., Krauss, R.M. (2021). Ion Mobility Lipoprotein Analysis. In: Davidson, M.H., Toth, P.P., Maki, K.C. (eds) Therapeutic Lipidology. Contemporary Cardiology. Humana, Cham. https://doi.org/10.1007/978-3-030-56514-5_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-56514-5_28

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-56513-8

  • Online ISBN: 978-3-030-56514-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation